SOPHiA GENETICS grants equity to CLO Van Well
Van Well Daan reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Van Well Daan reported acquisition or exercise transactions in this Form 4 filing.
SOPHiA GENETICS SA reported that Chief Legal Officer Daan Van Well received new equity compensation. He was granted options to buy 142,216 ordinary shares at $5.0400 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.
He was also granted 97,536 restricted stock units (RSUs), each representing one ordinary share. For these RSUs, 25% vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are compensation-related awards, not open-market share purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 239,752 shares
Grant/Award
2 txns
Insider
Van Well Daan
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 142,216 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 97,536 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 142,216 contracts (Direct);
Ordinary Shares — 97,536 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- F2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
Share options granted: 142,216 options
Option exercise price: $5.0400 per share
Option expiration: April 2, 2036
+4 more
7 metrics
Share options granted
142,216 options
Grant to Chief Legal Officer on April 2, 2026
Option exercise price
<money>$5.0400</money> per share
Exercise price for 142,216 options
Option expiration
<date>April 2, 2036</date>
Expiration date of granted share options
RSUs granted
97,536 RSUs
Restricted stock units granted under 2021 Equity Incentive Plan
Initial vesting date
<date>April 2, 2027</date>
25% of RSUs and 25% of options vest
Final RSU vesting
<date>April 2, 2030</date>
Remaining RSUs vest quarterly through this date
Final option vesting
<date>April 2, 2030</date>
Remaining options vest monthly through this date
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vest, share option, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"RSU grant made under the Issuer's 2021 Equity Incentive Plan."
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion or exercise price of 5.0400 for the share option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did SOPHiA GENETICS (SOPH) report for Daan Van Well?
SOPHiA GENETICS reported equity awards to Chief Legal Officer Daan Van Well, not open-market trades. He received 142,216 share options at $5.0400 per share and 97,536 restricted stock units, both subject to multi-year vesting schedules extending through April 2, 2030.
What are the details of the RSU grant to SOPHiA GENETICS (SOPH) CLO?
The Chief Legal Officer received 97,536 restricted stock units, each representing one ordinary share of SOPHiA GENETICS. Twenty-five percent vest on April 2, 2027, and the remaining 75% vest in equal quarterly installments through April 2, 2030, contingent on continued service.
Were the SOPHiA GENETICS Form 4 transactions open-market buys or sales?
The transactions were equity awards, not market trades. Both the 142,216 share options and 97,536 RSUs were granted as compensation at a reported price of $0.0000 per unit, with vesting conditions, rather than being bought or sold in the open market.
When do the SOPHiA GENETICS options granted to Daan Van Well vest and expire?
The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. They carry an exercise price of $5.0400 per share and expire on April 2, 2036, providing a long-term incentive window for the Chief Legal Officer.
What vesting schedule applies to SOPHiA GENETICS (SOPH) RSUs granted to the CLO?
The RSUs granted to the Chief Legal Officer vest over about three years. A 25% tranche vests on April 2, 2027, while the remaining 75% vest in equal quarterly installments through April 2, 2030, conditional on his continued service with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
